Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Study Details
Study Description
Brief Summary
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This trial is a prospective non-interventional observational study. The Chinese patients with lymphoma were included and the study data on driver gene abnormalities, demographic characteristics, clinicopathological characteristics and treatment were collected to evaluate the relevance of efficacy and disease prognosis.
Study Design
Outcome Measures
Primary Outcome Measures
- Incidence of driver gene abnormalities [from the day of the first patient was included to the date of the end of this trial, assessed up to 36 months]
the incidence of driver gene abnormalities by fixed gene testing technology
Secondary Outcome Measures
- objective response rate [from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months]
the total proportion of patients with complete response (CR) and partial response (PR)
- 5-year overall survival [from the date of the first patient was included to the date of the end of this trial, assessed up to 5 years]
from the date of first patient was included to the date of death by any cause
- Clinicopathological Characteristics [from the date of the first patient was included to the date of the end of this trial, assessed up to 36 months]
study data on clinicopathological characteristics related to incidence of driver gene abnormalities
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed as lymphoma (according to WHO 2017 classification criteria)
-
Life expectancy no less than 3 months
-
Agreeing to sign the written informed consents
Exclusion Criteria:
-
Other malignant tumor history or active malignant tumor need be treated
-
Researchers determine unsuited to participate in this trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university | Zhengzhou | Henan | China |
Sponsors and Collaborators
- Henan Cancer Hospital
Investigators
- Study Director: Yanyan Liu, M.D. Ph.D, Henan Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HNCH2019341